Bronchogen (AEDL) record · updated 20h ago
Bronchogen (AEDL) is a short synthetic tetrapeptide bioregulator studied in Russian research for supporting bronchial epithelial function and pulmonary tissue homeostasis.
How it works: Cell differentiation, anti-inflammatory effects, restoration of epithelial integrity
Development stage
where Bronchogen (AEDL) sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus and 1 registered trial. It describes the research record, not a recommendation.
Mass and formula from PubChem CID 11690869. No verified residue count for this compound.
| Study | Type | Year | Summary depth |
|---|---|---|---|
| Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. FindingNot reported in abstract. | Animal | 2015 | Full text read0.70 |
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Bronchogen (AEDL) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.